Stocktoria
Larimar Therapeutics, Inc. LRMR
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-06-19
Larimar Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| R&D expense | $154.2M | $73.3M | $27.7M | $24.2M | $38.4M | $31.4M | $20.8M | $47.9M | $40.8M | $39.9M |
| Operating income | -$172.5M | -$90.9M | -$41.8M | -$36.5M | -$50.5M | -$42.8M | -$23.2M | -$61.1M | -$53.0M | -$58.2M |
| Interest expense | — | — | — | — | — | — | $1.8M | $1.9M | $165,000 | $529,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.7M | -$80.6M | -$36.9M | -$35.4M | -$50.6M | -$42.5M | -$23.1M | -$61.4M | -$52.0M | -$57.9M |
| EPS (diluted) | — | $-1.32 | $-0.84 | $-1.37 | $-2.95 | $-3.57 | — | — | — | — |
| Operating cash flow | -$113.2M | -$70.8M | -$33.5M | -$27.6M | -$42.1M | -$42.2M | -$22.7M | -$51.5M | -$43.8M | -$52.0M |
| Free cash flow | -$113.3M | -$71.3M | -$33.6M | -$27.7M | -$42.4M | -$42.3M | -$22.8M | -$51.6M | -$43.8M | -$52.6M |
| Cash & equivalents | $85.4M | $33.2M | $26.7M | $26.8M | $70.1M | $68.1M | $1.0M | $49.3M | $40.8M | $32.4M |
| Total assets | $145.8M | $200.2M | $95.9M | $126.4M | $78.7M | $104.7M | $5.2M | $121.8M | $105.5M | $131.6M |
| Total liabilities | $67.8M | $28.4M | $14.2M | $15.5M | $14.3M | $15.0M | $5.9M | $28.5M | $27.3M | $9.9M |
| Shareholders' equity | $78.1M | $171.8M | $81.7M | $110.9M | $64.4M | $89.7M | -$694,000 | $2.9M | $78.2M | $121.7M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.